Results 101 to 110 of about 9,892 (240)

Pharmacokinetics, pharmacodynamics and safety of 15 mg-tolvaptan administered orally for 7 consecutive days to Chinese patients with child-Pugh B cirrhosis

Frontiers in Pharmacology
Background: Tolvaptan, a selective vasopressin V2-receptor antagonist, can elicit a diuretic effect without significant electrolyte loss. The aims were to evaluate multiple-dose pharmacokinetics, pharmacodynamics and safety of daily administration of 15 ...
Hongzhong Liu, Yongfeng Wang, Tao Liu, Yingxuan Chen, Xin Zheng, Ming Liu, Qian Zhao, Minde Zeng, Ji Jiang, Yimin Mao, Pei Hu   +10 more
doaj   +1 more source

Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy [PDF]

, 2017
The global nephrology community recognises the need for a cohesive plan to address the problem of chronic kidney disease (CKD). In July, 2016, the International Society of Nephrology hosted a CKD summit of more than 85 people with diverse expertise and ...
Bonventre, J, Coresh, J, Donner, J-A, Eckardt, K-U, Fogo, AB, Fox, CS, Gansevoort, RT, Heerspink, HJL, ISN Global Kidney Health Summit participants, Jardine, M, Kasiske, B, Kretzler, M, Köttgen, A, Levey, AS, Levin, A, Luyckx, VA, Mehta, R, Moe, O, Obrador, G, Pannu, N, Parikh, CR, Perkovic, V, Pollock, C, Stenvinkel, P, Tonelli, M, Tuttle, KR, Wheeler, DC   +26 more
core  

The efficacy and safety of Tolvaptan on treating congestive heart failure patients with hyponatremia [PDF]

, 2011
L. Ling, Z. Wen-ling, Biao Hua
openalex   +1 more source

The use of intermittent 7.5 mg tolvaptan on an out-patient basis for SIADH: a retrospective audit from a tertiary cancer hospital [PDF]

, 2015
Mohit Kumar, Lakshminarayanan Pichaipillai, Peter Trainer, Claire Higham   +3 more
openalex   +1 more source

Duloxetine-Induced Antidiuresis in Rats with Lithium-Induced Nephrogenic Diabetes Insipidus

Life
Antidepressants, including duloxetine, are a significant cause of drug-induced hyponatremia, which can disrupt the continuation of medication. Tolvaptan is beneficial for correcting hyponatremia caused by the syndrome of inappropriate antidiuresis, but ...
Sua Kim, Chor Ho Jo, Gheun-Ho Kim
doaj   +1 more source

Magnetic resonance imaging is effective for evaluating the therapeutic effect of tolvaptan on total kidney volume in patients with autosomal dominant polycystic kidney disease [PDF]

, 2018
Shuma Hirashio, Shigehiro Doi, Takao Masaki   +2 more
openalex   +1 more source

SO093LONGITUDINAL DATA ON TREATMENT DURATION AND COMPLIANCE FROM AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE CLINICAL TRIALS WITH TOLVAPTAN [PDF]

, 2020
Xiaolei Zhou, Diana Garbinsky, John Ouyang, Eric Davenport, Indra Agarwal, Dorothee Oberdhan   +5 more
openalex   +1 more source

Immediate drop of urine osmolality upon tolvaptan initiation predicts impact on renal prognosis in patients with ADPKD [PDF]

, 2023
Taro Akihisa, Hiroshi Kataoka, Shiho Makabe, Shun Manabe, Rie Yoshida, Yusuke Ushio, Masayo Sato, Aiji Yajima, Norio Hanafusa, Ken Tsuchiya, Kosaku Nitta, Junichi Hoshino, Toshio Mochizuki   +12 more
openalex   +1 more source

Insights into autosomal dominant polycystic kidney disease by quantitative mass spectrometry-based proteomics [PDF]

, 2018
Autosomal dominant polycystic kidney disease (ADPKD) is a common monogenetic disorder that is caused by mutations in the genes PKD1 and PKD2 encoding polycystin-1 and polycystin-2, respectively.
Dengjel, Jörn, Diedrich, Britta
core  

Tolvaptan [PDF]

Reactions Weekly, 2020
  +4 more sources